Refine by
Cardiac Tissue Articles & Analysis
26 news found
The dissociation of mouse heart tissue into single cells is a crucial step in many biomedical investigations. However, obtaining viable cells remains a challenge. Bertin Technologies’ Precellys multi-tissue dissociation kit, combined with the Precellys Evolution Touch, offers an effective solution to this problem. Our recent application note demonstrated a cell viability rate of 87.35%, ...
Each tissue microarray is constructed from paraffin-embedded (FFPE) tissue blocks from a specific number of donor cases. ...
https://www.termis.org/wc2018/ On September 7th, CSO speaks about monogenic disease modeling using NuHeart™ technology during TERM for heart, blood vessel & lung session. 99-O-5: Personalized micro-3D human heart tissues for orphan drug development Tetsuro Wakatsuki,Neil Daily,Pinar Kemanli, Michael Greenberg,Jennifer Strande InvivoSciences, Inc. Madison Wisconsin, USA, ...
The Microplate Reader Company – and InvivoSciences, Inc. – a leader in stem cell tissue engineering providing a novel solution in first-in-class drug discovery – announced today a strategic collaboration to market the time-dependent fluorescent assessment of engineered 3D heart tissues using advanced microplate reader technologies. Employing an automated system, 3D heart ...
IVS’s functional 3D tissue models reconstitute the physiological properties of human cardiac, smooth and skeletal muscle as well as connective tissues that support cancer growth. Our lead product is 3D cardiac engineered heart tissues (EHTs) fabricated from human induced pluripotent stem cell (iPSC) derived ...
IVS’s Functional 3D tissue models recapitulate the physiological properties of human cardiac, smooth and skeletal muscle and connective tissue. Application of induced pluripotent technology allows to fabricate tissues in diseased states, e.g., hereditary cardiac diseases, cardiac fibrosis, ...
Valo Health, Inc (“Valo”) shared the initial results of a collaborative study with the U.S. Food and Drug Administration (FDA), demonstrating the potential of Valo’s Biowire platform to predict clinical efficacy of Cardiac Contractility Modulation ...
The investigational gene therapy is administered directly to the heart muscle through a mini-thoracotomy by an experienced cardiac surgeon. The EXACT Trial is being conducted at top cardiovascular research sites across the United States. ...
The investigational gene therapy is administered directly to the heart muscle through a mini-thoracotomy by an experienced cardiac surgeon at top cardiovascular research sites across the United States. ...
Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced that it has expanded its existing collaboration with Advanced BioMatrix, a division of BICO Group AB (STO: BICO), for Lineage’s HyStem cell/drug delivery technology. Under the expanded collaboration, Advanced ...
We are incredibly excited by the potential for this investigational therapy to improve the quality of life for these cardiac patients.” “In many other gene therapy trials, safety concerns arose due to systemic administration of high viral particle loads,” added Dr. ...
XyloCor has a second preclinical investigational product, XC002, in discovery stage, being developed for the treatment of patients with cardiac tissue damage from heart attacks. The company, which was co-founded by Ronald Crystal, MD, and Todd Rosengart, MD, has an exclusive license from Cornell ...
The models will be used with a specialized station and cardiac pump, allowing the valves to open and close to mimic a beating heart. ...
ByBIOMODEX
VANCOUVER, British Columbia – Kardium Inc. announces the completion of successful first-in-human (FIH) procedures with the Globe Pulsed Field System. Dr. Vivek Reddy of Mount Sinai Hospital in New York, USA and Prof. Petr Neužil of Na Homolce Hospital in Prague, Czech Republic, performed the procedures in Prague last week. Dr. Jacob Koruth of Mount Sinai Hospital joined Dr. Reddy and Prof. ...
“Our vision for the future of this new energy source is to deliver it via a force sensing focal point ablation catheter and to guide that delivery with advanced 3D cardiac mapping, rather than fluoroscopy. This approach is different from many others entering this field, in that it will allow precise applications of PFA in highly targeted tissue across the ...
The investigational gene therapy will be administered directly to the muscle tissue of the heart by an experienced cardiac surgeon. The EXACT Trial was initiated in 2020 and is ongoing at top cardiovascular research sites across the United States. ...
The acquisition will complement the existing Boston Scientific electrophysiology portfolio to include the FARAPULSE Pulsed Field Ablation (PFA) System – a non-thermal ablation system for the treatment of atrial fibrillation (AF) and other cardiac arrhythmias. "The emerging field of PFA has the potential to alter the future of ablation therapy and has shown the promise of ...
The system incorporates major features of living biology, such as pulsatile fluid flow, mechanical and electrical coupling, and physiological tissue-to-fluid and tissue-to-tissue ratios. This supports the development of a large variety of substance assays, ranging from acute and repeated dose toxicity assays to long-term disease treatment ...
FARAPULSE Inc. today announced the first patients were treated in the ADVENT Trial, a U.S. Food and Drug Administration (FDA) Investigational Device Exemption (IDE) pivotal trial to evaluate the safety and effectiveness of its Pulsed Field Ablation (PFA) system for the treatment of paroxysmal Atrial Fibrillation (AF). AF is a heart rhythm disorder that affects nearly 6 million Americans and makes ...
Life-threatening heart rhythm disorders such as ventricular tachycardia may be eliminated using cutting-edge, non-invasive technology as an alternative to standard invasive catheter ablation procedures, in some cases. In an abstract and associated poster published at the American College of Physicians’ Southern Regional Conference, researchers report successful use of vMap™ ...